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INTRODUCTION
Numerous studies explored the efficacy of vitamin C in
the treatment of cancer, but their mixed findings caused a
great deal of controversy. In 1949, Klenner first suggested
the possibility of using vitamin C for the treatment of can-
cer. In 1952, McCormick asserted that vitamin C has been
proposed as a chemotherapeutic agent. Hundreds of articles
including an array of in vitro, in vivo, cell culture, animal,
and human studies have been published on this topic. As a
result, it is believed that vitamin C might have anti-cancer
effects (1-3).
Twenty-six years ago, Cameron et al. reported that they
increased the time of survival of cancer patients and improved
their quality of life by administrating high doses of vitamin
C (4). As a result, Pauling and Cameron continuously assert-
ed the effect of vitamin C on cancer. However, Moertel et al.
(Mayo Clinic) reported that high-dose vitamin C therapy
was not effective against advanced cancer (5). This finding
is critical because it may prevent clinicians from using vita-
min C for cancer patients.
A critical point of both studies (Cameron et al. and Moer-
tel et al.) is that they used a different administration method,
intravenous route in the former and oral route of vitamin C
in the latter. Oral absorption of vitamin C cannot achieve
plasma concentrations comparable to those obtained by intra-
venous administration. Moreover, it has been recently report-
ed that vitamin C acts as a toxic agent against cancer cells
when given intravenously (6). 
Unlike most mammals, human and other primates cannot
synthesize vitamin C from glucose due to L-gulonolactone
oxidase deficiency. Therefore, we must be obtained adequate
amounts of this nutrient from foods and supplements. Vita-
min C plays a crucial role in the synthesis of L-carnitine from
lysine, neurotransmitters synthesis, cytochrome p-450 activ-
ity, cholesterol metabolism, detoxification of exogenous com-
pounds and as an antioxidant (7-10). In addition, when given
in large doses, vitamin C may function as an ergogenic agent
(11). Because the levels of vitamin C in the blood of the can-
cer patients were significantly decreased compared to healthy
persons, cancer patients required larger amounts of vitamin
C (12, 13). 
Improved health-related quality of life is important as much
as a cure of cancer in terminally ill cancer patients who have
an estimated survival of less than 6 months. The objective
of this study was to examine changes in the quality of life in
terminally ill cancer patients after administration of high-
doses of vitamin C. 
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Changes of Terminal Cancer Patients' Health-related Quality of Life
after High Dose Vitamin C Administration
Over the years there has been a great deal of controversy on the effect of vitamin
C on cancer. To investigate the effects of vitamin C on cancer patients’ health-relat-
ed quality of life, we prospectively studied 39 terminal cancer patients. All patients
were given an intravenous administration of 10 g vitamin C twice with a 3-day inter-
val and an oral intake of 4 g vitamin C daily for a week. And then we investigated
demographic data and assessed changes in patients’ quality of life after adminis-
tration of vitamin C. Quality of life was assessed with EORTC QLQ-C30. In the glob-
al health/quality of life scale, health score improved from 36± ±18 to 55± ±16 after
administration of vitamin C (p=0.001). In functional scale, the patients reported sig-
nificantly higher scores for physical, role, emotional, and cognitive function after ad-
ministration of vitamin C (p<0.05). In symptom scale, the patients reported signifi-
cantly lower scores for fatigue, nausea/vomiting, pain, and appetite loss after admin-
istration of vitamin C (p<0.005). The other function and symptom scales were not
significantly changed after administration of vitamin C. In terminal cancer patients,
the quality of life is as important as cure. Although there is still controversy regard-
ing anticancer effects of vitamin C, the use of vitamin C is considered a safe and
effective therapy to improve the quality of life of terminal cancer patients.
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MATERIALS AND METHODS
Study subjects
Outpatients with terminal cancer who were treated in the
Department of Family Medicine, Myungji-Hospital, Kwan-
dong University College of Medicine from 1 February 2004
through 31 August 2005, were included in the study. The
study included 39 cancer patients (male: 20, female: 19) after
excluding those who were undergoing chemotherapy. 
Assessment of cancer patients’ life-related quality 
A written consent was obtained from all patients. They
were given an intravenous administration of 10 g vitamin C
twice with a 3-day interval and an oral intake of 4 g vitamin
C daily for a week. And then we investigated demographic
data and assessed changes in patients’ quality of life 1 week
after administration of vitamin C.
Demographic data included sex, age, cancer diagnosis, anti-
cancer therapy, recurrence, metastasis and performance sta-
tus (Eastern Cooperative Oncology Group, ECOG). Quality
of life was assessed by the European Organization for Research
and Treatment of cancer (EORTC). This was a self-adminis-
trated questionnaire (EORTC) that was used to assess the
quality of life of the patients. When a patient was unable to
self-administer the questionnaire, an interviewer or the pa-
tient’s caregiver completed the questionnaire after finding
out answers from the patient. The Korean version of the Euro-
pean Organization for Research and Treatment of cancer core
quality-of-life questionnaire (EORTC QLQ-C30) was used
as the questionnaire. It was designed to ask clinical symptoms
experienced by the patients during the previous week. The
questionnaire consists of 30 items, that comprise a global
evaluation of health status and quality of life, five functions
(physical, role, emotional, cognitive, and social), three symp-
toms (fatigue, pain, and nausea/vomiting), and six additional
single items (dyspnea, appetite loss, sleep disturbance, con-
stipation, diarrhea, and financial impact of the disease and
treatment) (14). Scores for each scale on the EORTC QLQ-
C30 questionnaire were calculated as suggested by the EO-
RTC Study Group on Quality of Life. All of the scales and
single-item measures ranged in score from 0 to 100. A high
scale score represents a higher response level. Thus a high
score for the global health status/quality of life represents a
high quality of life and a high score for a functional scale rep-
resents a high/health level of functioning. But a high score
for a symptom scale/item represents a high level of symp-
tomatology/problems. 
Statistical analysis 
The EORTC scales scores before and after administration
of vitamin C, were compared using the Wilcoxon signed
rank-test. A p-value of less than 0.05 is considered statisti-
cally significant. 
RESULTS
Demographic data
The demographic data (age, sex, cancer diagnosis, anti-
cancer therapy, metastasis, performance status) are shown in
Table 1. All patients were stage IV, and 12 (30.8%) patients
experienced a recurrence of their cancers. No patients were
excluded due to side effects of vitamin C.
Quality of life (EORTC)
The quality of life before and after administration of high
dose vitamin C, are shown in Table 2. In the global health/
quality of life scale, health score improved from 36±18 to
55±16 after administration of vitamin C (p=0.001). In fun-
ctional scales, the patients reported significantly higher scores
for physical, role, emotional, cognitive, and social function
after administration of vitamin C (p<0.005). In symptom
scales, the patients reported significantly lower scores for fa-
tigue, nausea/vomiting, pain, sleep disturbance, and appetite
loss after administration of vitamin C (p<0.005). The other
symptom scales such as dyspnea, constipation, diarrhea, fin-
ancial impact were not significantly changed after adminis-
Characteristics Number (%)
Sex
Male 20 (51.3)
Female 19 (48.7)
Age (mean±SD, yr) 53.5±10.5
Cancer diagnosis
Stomach 10 (25.6)
Lung 7 (17.9)
Liver 1 (2.6)
Breast 4 (10.3)
Cervix 1 (2.6)
Colo-rectal 9 (23.1)
Biliary 2 (5.1)
Other 5 (12.8)
Previous anticancer therapy
Surgery 1 (2.6)
Chemotherapy (CTx) 11 (28.2)
Radiotherapy (RTx) 1 (2.6)
Surgery+CTx 19 (48.7)
CTx+RTx 3 (7.7)
Surgery + CTx+RTx 4  (10.3)
Recurrence 12 (30.8)
Metastasis 39 (100.0)
Performance status (ECOG)
0-1 26 (66.6)
2-4 13 (33.4)
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tration of vitamin C. 
DISCUSSION
In terminal cancer patients, the quality of life is as impor-
tant as cure. The treatment for terminal cancer patients was
particularly focused on the patient’s well-being in addition
to the efforts to minimize symptoms. Thus, the ultimate goal
of treatment for terminal cancer patients can differ from those
pursued in treatments designed to cure.
If terminal cancer patients were concerned about emotion-
al changes and functional impairment and if the patients’
quality of life did not improve, the treatment that they under-
went should not be considered successful even though it ex-
tended their life expectancy. Although investigators are divid-
ed in their opinions on whether vitamin C is effective for the
treatment of cancers, many of them reported that cancer pa-
tients showed improvement in their quality of life.
This study also demonstrated improvement in global health/
quality of life in terminal cancer patients after administra-
tion of vitamin C along with improvements in all functions
(physical, role, emotional, cognitive, and social) and some
symptoms (fatigue, nausea/vomiting, pain, sleep disturbance,
and appetite loss).
The therapeutic impacts of vitamin C, expected when ad-
ministered to terminal cancer patients, include anticancer
effects, positive impact on the central nervous system and
mental ability, pain relief and contribution to energy gener-
ation. The anticancer effects of vitamin C boost cytotoxicity
of tumor cells, collagen synthesis, antioxidant action, immu-
nity system and low concentration of certain amino acids.
First, the mechanism underlying the action of vitamin C in
combating cancer cells explains that vitamin C in blood is
oxidized to dehydroascorbate acid, which passes freely back
and forth through the cell membranes via glucose transport.
When dehydroascorbate acid enters cancer cells, glutathione
turned the dehydroascorbate back into ascorbic acid (vitamin
C), which is not allowed to move out of cancer cells. This
ascorbic acid is converted to dehydroascorbate again and pro-
duces H2O2, which destroy cancer cells (15). Higher levels
of ascorbic acid were observed around cancer cells when com-
pared to normal cells (16). Casciari et al. study reported tumor
cells apoptosis occurred in 42.9% of total patients and necro-
sis in 24.4% when patients’ blood level of vitamin C was 11.2
mM. They said apoptosis increased to 57.6% and necrosis
to 33.1%, respectively, when patients’ blood level of vitamin
C rose to 33.7 mM (17). Secondly, an increase in the synthe-
sis of collagen inhibits the growth of cancer cells, leading to
apoptosis and necrosis in cancer cells (18). That is, cancer cells
releases collagenase and dissove collagen between cells/tissues.
This means that these enzymes dissolve basement membranes,
an organization of collagen and extracellular matrices, enabling
cancer cells to infiltrate and destroy adjacent normal tissues.
An increase in collagen synthesis due to vitamin C would
however increase membrane mechanical integrity and cohe-
sion and eventually prevent the growth of cancer cells. Third-
ly, antioxidant properties of vitamin C inhibit cancer growth
induced by free radicals (3, 19). It is however an interesting
fact that vitamin C is taken up in oxidized form by cancer
cells. Fourthly, vitamin C enhances the immune system by
elevating the production of infection-fighting white blood
cells and interferon levels, so cancer cells are suppressed or
eliminated (20, 21). Last, the vitamin C can change the lev-
els of certain amino acids in body fluids and may deplete the
bioavailability of lysine and cyteine, 2 amino acids that re-
quired for rapidly growing tumors (22, 23).
The impact of vitamin C on the central nervous system and
mental ability is based on the following mechanisms: First,
increased c-AMP enables vitamin C to block phosphodi-
esterase, so the breakdown of c-AMP can be prevented (24).
An increase in blood c-AMP levels therefore boosts mental
ability. Secondly, vitamin C also prevents the formation of
toxic neurotransmitters. Vitamin C deficiency triggers the
oxidation of adrenalin and noradrenalin, and adrenochrome
and noradrenochrome are generated, respectively, and their
toxic effects pose various problems (25).
The impact of vitamin C on pain relief is explained by vari-
ous mechanisms (26). First, vitamin C has anti-inflammato-
ry effects by stimulating c-AMP production, which in turn
elevates production of steroid in the ACTH. Secondly, vitamin
C works to help decrease blood calcium levels and enhances
calcium uptake in bone. As a result, bone pain is relieved (27).
It was recently discovered that vitamin C also supports the
body’s energy generation (28). The mechanism of ergogenic
activity of vitamin C is probably due to vitamin C’s oxidation
EORTC (Mean±SD)
Before After
p-value
Global Health Scale
Global health 36±18 55±16 0.001
Function scale
Physical 66±20 72±15 0.037
Role 59±31 73±22 0.002
Emotional 68±24 78±19 0.001
Cognitive 69±23 80±16 0.002
Social 62±34 71±24 0.049
Symptom scale
Fatigue 52±24 40±19 0.001
Nausea/Vomiting 24±25 11±15 0.001
Pain 30±32 21±25 0.013
Dyspnea 23±28 15±20 0.051
Sleep disturbance 32±35 26±25 0.029
Appetite loss 50±43 31±29 0.005
Constipation 19±26 16±25 0.390
Diarrhea 16±24 11±18 0.218
Financial impact 25±27 23±24 0.914
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reduction potential, capable of providing necessary electrons
to the electron transport system in the mitochondria for in-
creased energy production. 
Since Szent-Gyorgyi reported the efficacy of vitamin C for
the first time in 1928, studies in the same area have contin-
ued and anticancer effects of vitamin C are still under debate.
While Cameron et al. suggested beneficial effects of vitamin
C on the treatment of cancer (4), the Mayo Clinic study report-
ed no anticancer effects of vitamin C (5). Investigators cited
the different administration method as the reason for such
opposite results. The former used intravenous vitamin C ad-
ministration at a dose of 10 g and subsequent oral adminis-
tration, whereas the latter used oral administration only. Pa-
dayatty et al. proved that it was difficult to increase vitamin
C level to more than 220 M/L in blood through oral admin-
istration and that blood levels of vitamin C that are required
for combating cancer could be achieved through intravenous
adminstration (6). Their findings provided the scientific basis
for using intravenous administration in cancer patients.
Vitamin C is a water-soluble and remarkably nontoxic at
high levels. Nevertheless, this treatment should be adminis-
tered with caution to patients with glucose-6-phosphate de-
hydrogenase (G6PD) deficiency (29). When given high doses
of vitamin C, these patients may have the risk of developing
hemolysis. Before applying vitamin C therapy, patients should
be screened for this deficiency. 
Although there is still controversy regarding anticancer
effects of vitamin C, the use of vitamin C is considered the
safe and effective therapy to improve the quality of life in
terminal cancer patients. The further study is required to com-
pare effects of vitamin C in between placebo and vitamin C
group in terminal cancer patients with well-designed exper-
imental strategy.
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